Industry officials report mixed experiences with recent FDA pilot programs
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesCDERModeling and simulationNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesCDERModeling and simulationNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy